Recurrent Waldenstrom Macroglobulinemia: Clinical Trials

12 trials for Recurrent Waldenstrom Macroglobulinemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 8 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 3, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 28Completed 3, Terminated 3, Active not recruiting 1, Recruiting 1

Follow Recurrent Waldenstrom Macroglobulinemia: new trials by email Literature Review of Recurrent Waldenstrom Macroglobulinemia trials Research Report on Recurrent Waldenstrom Macroglobulinemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Phase 1 / Phase 2RecruitingMayo Clinic382026-09-302026-10-05
Q702 for the Treatment of Patients With Hematologic Malignancies
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Phase 1RecruitingMayo Clinic462025-08-272025-10-10
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 1WithdrawnYazeed Sawalha2022-09-302022-09-30
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Phase 2TerminatedMayo Clinic212018-08-142026-05-05
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma
Phase 2TerminatedUniversity of Washington42017-12-182020-01-18
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center1502017-09-112026-05-14
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2Active not recruitingBarbara Ann Karmanos Cancer Institute432017-06-202026-10-23
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Phase 1 / Phase 2CompletedDavid Bond, MD362017-02-142026-09-23
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Phase 1CompletedKami Maddocks22017-01-122019-07-30
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 2CompletedMayo Clinic652015-02-192026-06-24
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)92011-07-202021-10-04
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Pomalidomide - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Phase 1TerminatedM.D. Anderson Cancer Center152010-10-062025-09-04

Narrower conditions

Waldenstrom Macroglobulinemia (12)  ·  Lymphoma, B-Cell, Marginal Zone (8)  ·  Lymphoma, Follicular (7)  ·  Lymphoma, Mantle-Cell (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Lymphoma, B-Cell (4)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (2)  ·  Burkitt Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myelodysplastic Syndromes (2)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Erdheim-Chester Disease (1)  ·  Hematologic Diseases (1)  ·  Histiocytic Sarcoma (1)

Broader conditions

Blood Protein Disorders (12)  ·  Cardiovascular Diseases (12)  ·  Hemic and Lymphatic Diseases (12)  ·  Hemorrhagic Disorders (12)  ·  Hemostatic Disorders (12)  ·  Immune System Diseases (12)  ·  Immunoproliferative Disorders (12)  ·  Lymphatic Diseases (12)  ·  Lymphoproliferative Disorders (12)  ·  Neoplasms (12)  ·  Neoplasms by Histologic Type (12)  ·  Neoplasms, Plasma Cell (12)  ·  Paraproteinemias (12)  ·  Vascular Diseases (12)  ·  Hematologic Diseases (11)

Interventions

ibrutinib (3)  ·  Biopsy (2)  ·  CT-P10 (2)  ·  Lenalidomide (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Rituximab (2)  ·  Sirolimus (2)  ·  Specimen Handling (2)  ·  pembrolizumab (2)  ·  Bortezomib (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Dexamethasone (1)

Sponsors

Mayo Clinic (4)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  David Bond, MD (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Kami Maddocks (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  University of Washington (1)  ·  Yazeed Sawalha (1)

Countries

United States (11)

Top investigators

Asher A. Chanan-Khan, M.D. (1)  ·  David Bond, MD (1)  ·  Dipenkumar Modi, M.D. (1)  ·  Jithma P. Abeykoon, MD (1)  ·  Kami Maddocks, MD (1)  ·  Leonard T Heffner (1)  ·  Masumi Ueda Oshima (1)  ·  Prashant Kapoor, MD (1)  ·  Sheeba K Thomas (1)  ·  Stephen Smith (1)  ·  Wei Ding (1)  ·  Yazeed Sawalha, MD (1)

Results publications

PMID 28424162, PMID 33785483, PMID 41043099

NIH funding

P30CA015704 (2), P01CA078902 (1), P30CA016058 (1), P30CA022453 (1), P50CA097274 (1), U10CA021115 (1), U10CA180820 (1)